<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-1-16-23</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2444</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS AND METHODS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Analysis of the migraine characteristics in the perimenopause</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ особенностей течения мигрени в перименопаузе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-3192-1936</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климентова</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimentova</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Диана Андреевна Климентова</p><p>119021, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Diana Andreevna Klimentova</p><p>11, Rossolimo St., Build. 1, Moscow 119021</p></bio><email xlink:type="simple">klimentovadiana23@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3833-532X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табеева</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tabeeva</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119021, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>11, Rossolimo St., Build. 1, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского, ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Института клинической медицины им. Н.В. Склифосовского, ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>02</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><fpage>16</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Klimentova D.A., Tabeeva G.R., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Климентова Д.А., Табеева Г.Р.</copyright-holder><copyright-holder xml:lang="en">Klimentova D.A., Tabeeva G.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2444">https://nnp.ima-press.net/nnp/article/view/2444</self-uri><abstract><p>Characteristics of migraine in perimenopause have not been sufficiently analyzed.</p><sec><title>Objective</title><p>Objective. To compare the course of migraine in patients of reproductive age (RA) and in perimenopause.</p></sec><sec><title>Material and methods</title><p>Material and methods. The observational cross-sectional study involved 120 women suffering from migraine: 60 in the RA group (mean age – 32.28 years), 60 in the perimenopause group (mean age – 48.13 years). Patients were interviewed and questionnaires were filled in, HIT-6, MIBS-4, HURT, Migraine ACT, MIDAS, SF-36, HADS and ISQ scales were used.</p></sec><sec><title>Results</title><p>Results. The indicators of pain intensity, the duration of attacks and the number of days with headache per month are significantly higher in perimenopause than in RA (p&lt;0.05). The risk of severe impact of headache on quality of life (HIT-6) and migraine burden outside of attacks (MIBS-4) are also significantly higher in perimenopause than in RA (OR=1.9 and OR=1.7, respectively; p&gt;&lt;0.05), and most quality of life indicators (SF-36) are lower (p&gt;&lt;0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p&gt;&lt;0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p&gt;&lt;0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.&gt;&lt;0.05) The risk of severe impact of headache on quality of life (HIT-6) and migraine burden outside of attacks (MIBS-4) are also significantly higher in perimenopause than in RA (OR=1.9 and OR=1.7, respectively; p&lt;0.05), and most quality of life indicators (SF-36) are lower (p&gt;&lt;0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p&gt;&lt;0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p&gt;&lt;0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.&gt;&lt;0.05) ), and most quality of life indicators (SF-36) are lower (p&lt;0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p&gt;&lt;0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p&gt;&lt;0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.&gt;&lt;0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p&lt;0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p&lt;0.05)</p></sec><sec><title>Conclusion</title><p>Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Особенности течения мигрени в перименопаузе в настоящее время недостаточно изучены.</p><p>Цель исследования – сравнение течения мигрени у пациенток в репродуктивном периоде (РП) и в перименопаузе.</p><sec><title>Материал и методы</title><p>Материал и методы. В обсервационное одномоментное исследование включено 120 женщин, страдающих мигренью: 60 – в группу РП (средний возраст – 32,28 года), 60 – в группу перименопаузы (средний возраст – 48,13 года). Проведены опрос и анкетирование пациенток при помощи шкал HIT-6, MIBS-4, HURT, Migraine-ACT, MIDAS, SF-36, HADS и ISQ.</p></sec><sec><title>Результаты</title><p>Результаты. Показатели интенсивности боли, продолжительности приступов, числа дней с головной болью в месяц значимо больше в перименопаузе, чем в РП (p&lt;0,05). Риск тяжелого влияния головной боли на качество жизни (HIT-6) и бремя мигрени вне приступов (MIBS-4) также значимо выше в перименопаузе, чем в РП (ОР=1,9 и ОР=1,7 соответственно; p&gt;&lt;0,05), а большая часть показателей качества жизни (SF-36) – ниже (p&gt;&lt;0,05). Риск артериальной гипертензии и заболеваний опорно-двигательного аппарата в перименопаузе выше, чем в РП (ОР=2,8 и ОР=4,25 соответственно; p&gt;&lt;0,05). Риск клинически выраженной тревоги и бессонницы в перименопаузе выше, чем в РП (ОР=2,4 и ОР=5,15; p&gt;&lt;0,05). Заключение. Течение мигрени у женщин в перименопаузе менее благоприятное, чем в РП. Для установления причин наблюдаемых явлений и разработки клинических рекомендаций по ведению пациенток с мигренью в перименопаузе необходимы дальнейшие исследования.&gt; &lt;0,05). Риск тяжелого влияния головной боли на качество жизни (HIT-6) и бремя мигрени вне приступов (MIBS-4) также значимо выше в перименопаузе, чем в РП (ОР=1,9 и ОР=1,7 соответственно; p p&lt;0,05). ), а большая часть показателей качества жизни (SF-36) – ниже (p&lt;0,05). Риск артериальной гипертензии и заболеваний опорно-двигательного аппарата в перименопаузе выше, чем в РП (ОР=2,8 и ОР=4,25 соответственно; p &lt;0,05). Риск клинически выраженной тревоги и бессонницы в перименопаузе выше, чем в РП (ОР=2,4 и ОР=5,15; p&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Течение мигрени у женщин в перименопаузе менее благоприятное, чем в РП. Для установления причин наблюдаемых явлений и разработки клинических рекомендаций по ведению пациенток с мигренью в перименопаузе необходимы дальнейшие исследования.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мигрень</kwd><kwd>перименопауза</kwd><kwd>репродуктивный период</kwd><kwd>качество жизни</kwd></kwd-group><kwd-group xml:lang="en"><kwd>migraine</kwd><kwd>perimenopause</kwd><kwd>reproductive period</kwd><kwd>quality of life</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Российское общество акушеров-гинекологов. Менопауза и климактерические состояния у женщины. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/117_2.</mixed-citation><mixed-citation xml:lang="en">Russian Society of Obstetricians and Gynecologists. Menopause and climacteric conditions in women. Clinical guidelines. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Юренева СВ, Ильина ЛМ, Сметник ВП. Старение репродуктивной системы женщин: от теории к клинической практике. Часть I. Эндокринные и клинические характеристики стадий репродуктивного старения женщин. Акушерство и гинекология. 2014;(3):21-7.</mixed-citation><mixed-citation xml:lang="en">Yureneva SV, Ilyina LM, Smetnik VP. Aging of the female reproductive system: from theory to clinical practice. Part I. Endocrine and clinical characteristics of the stages of female reproductive aging. Akusherstvo i ginekologiya. 2014;(3):21-7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x</mixed-citation><mixed-citation xml:lang="en">Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073</mixed-citation><mixed-citation xml:lang="en">Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar;24(1):11-8. doi: 10.1177/2053369117731172. Epub 2017 Oct 10.</mixed-citation><mixed-citation xml:lang="en">MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar;24(1):11-8. doi: 10.1177/2053369117731172. Epub 2017 Oct 10.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Oh K, Jung KY, Choi JY, et al. Headaches in middle-aged women during menopausal transition: a headache clinic-based study. Eur Neurol. 2012;68(2):79-83. doi: 10.1159/000336838. Epub 2012 Jul 3.</mixed-citation><mixed-citation xml:lang="en">Oh K, Jung KY, Choi JY, et al. Headaches in middle-aged women during menopausal transition: a headache clinic-based study. Eur Neurol. 2012;68(2):79-83. doi: 10.1159/000336838. Epub 2012 Jul 3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.</mixed-citation><mixed-citation xml:lang="en">Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019 Jun;85(6):865-74. doi: 10.1002/ana.25476. Epub 2019 Apr 30.</mixed-citation><mixed-citation xml:lang="en">Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019 Jun;85(6):865-74. doi: 10.1002/ana.25476. Epub 2019 Apr 30.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Alebna P, Maleki N. Allostatic Load in Perimenopausal Women With Migraine. Front Neurol. 2021 Apr 22;12:649423. doi: 10.3389/fneur.2021.649423</mixed-citation><mixed-citation xml:lang="en">Alebna P, Maleki N. Allostatic Load in Perimenopausal Women With Migraine. Front Neurol. 2021 Apr 22;12:649423. doi: 10.3389/fneur.2021.649423</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y, Tang R, Li J, et al. Generalized headache among Chinese climacteric women: findings from a prospective cohort. Climacteric. 2021 Jun;24(3):289-96. doi: 10.1080/13697137.2021.1881058. Epub 2021 Feb 17.</mixed-citation><mixed-citation xml:lang="en">Gao Y, Tang R, Li J, et al. Generalized headache among Chinese climacteric women: findings from a prospective cohort. Climacteric. 2021 Jun;24(3):289-96. doi: 10.1080/13697137.2021.1881058. Epub 2021 Feb 17.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x</mixed-citation><mixed-citation xml:lang="en">Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas. 2020 Dec;142:24-30. doi: 10.1016/j.maturitas.2020.07.005. Epub 2020 Jul 10.</mixed-citation><mixed-citation xml:lang="en">MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas. 2020 Dec;142:24-30. doi: 10.1016/j.maturitas.2020.07.005. Epub 2020 Jul 10.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lagman-Bartolome AM, Lay C. Migraine in Women. Neurol Clin. 2019 Nov;37(4):835-45. doi: 10.1016/j.ncl.2019.07.002. Epub 2019 Aug 22.</mixed-citation><mixed-citation xml:lang="en">Lagman-Bartolome AM, Lay C. Migraine in Women. Neurol Clin. 2019 Nov;37(4):835-45. doi: 10.1016/j.ncl.2019.07.002. Epub 2019 Aug 22.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Карпова МИ, Заряда АА, Долгушина ВФ и др. Мигрень у женщин: клинические и терапевтические аспекты. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(3):98-107. doi: 10.17116/jnevro201911903198.</mixed-citation><mixed-citation xml:lang="en">Karpova MI, Zariada AA, Dolgushina VF, et al. Migraine in women: clinical and therapeutical aspects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):98- 107. doi: 10.17116/jnevro201911903198 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-66. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9.</mixed-citation><mixed-citation xml:lang="en">Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-66. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Faubion SS, Batur P, Calhoun AH. Migraine Throughout the Female Reproductive Life Cycle. Mayo Clin Proc. 2018 May;93(5):639-45. doi: 10.1016/j.mayocp.2017.11.027</mixed-citation><mixed-citation xml:lang="en">Faubion SS, Batur P, Calhoun AH. Migraine Throughout the Female Reproductive Life Cycle. Mayo Clin Proc. 2018 May;93(5):639-45. doi: 10.1016/j.mayocp.2017.11.027</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Максюкова ЕВ, Осипова ВВ. Мигрень у пациентов старшей возрастной группы: клинико-психологический анализ. Российский журнал боли. 2011;(2):33.</mixed-citation><mixed-citation xml:lang="en">Maksyukova EV, Osipova VV. Migraine in older patients: clinical and psychological analysis. Rossiyskiy zhurnal boli. 2011;(2):33 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, VanderPluym JH, Halker Singh RB, et al. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease: A Target Trial Emulation. Mayo Clin Proc. 2024 Nov;99(11):1722-31. doi: 10.1016/j.mayocp.2024.03.023. Epub 2024 Aug 30.</mixed-citation><mixed-citation xml:lang="en">Wang Z, VanderPluym JH, Halker Singh RB, et al. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease: A Target Trial Emulation. Mayo Clin Proc. 2024 Nov;99(11):1722-31. doi: 10.1016/j.mayocp.2024.03.023. Epub 2024 Aug 30.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma P, Varghese Gupta S, Bhatt P, et al. Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Can J Physiol Pharmacol. 2024 Oct 22. doi: 10.1139/cjpp2024-0117. Epub ahead of print.</mixed-citation><mixed-citation xml:lang="en">Sharma P, Varghese Gupta S, Bhatt P, et al. Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Can J Physiol Pharmacol. 2024 Oct 22. doi: 10.1139/cjpp2024-0117. Epub ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen CL, Hougaard A, Gaist D, Hallas J. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol. 2024 Mar 1;81(3):248-54. doi: 10.1001/jamaneurol.2023.5549</mixed-citation><mixed-citation xml:lang="en">Petersen CL, Hougaard A, Gaist D, Hallas J. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol. 2024 Mar 1;81(3):248-54. doi: 10.1001/jamaneurol.2023.5549</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133.</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Данилов АБ, Корешкина МИ и др. Опыт применения российского ризатриптана 10 мг в таблетках в рутинной клинической практике: результаты многоцентрового пострегистрационного наблюдательного исследования «ОПЫТ». Неврология, нейропсихиатрия, психосоматика. 2024;16(5):60-8. doi: 10.14412/2074-2711-2024-5-60-68.</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Danilov AB, Koreshkina MI, et al. Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT”. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(5):60-8. doi: 10.14412/2074-2711-2024-5-60-68 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M. Cardiovascular safety of using nonsteroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study. Rheumatol Int. 2024 Jun;44(6):1061-9. doi: 10.1007/s00296-024-05584-7. Epub 2024 Apr 6.</mixed-citation><mixed-citation xml:lang="en">Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M. Cardiovascular safety of using nonsteroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study. Rheumatol Int. 2024 Jun;44(6):1061-9. doi: 10.1007/s00296-024-05584-7. Epub 2024 Apr 6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol. 2004 Jun;60(4):279-83. doi: 10.1007/s00228-004-0761-0. Epub 2004 Apr 22.</mixed-citation><mixed-citation xml:lang="en">Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol. 2004 Jun;60(4):279-83. doi: 10.1007/s00228-004-0761-0. Epub 2004 Apr 22.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine DrugsLasmiditan, Gepants, and Calcitonin-GeneRelated Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180</mixed-citation><mixed-citation xml:lang="en">Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine DrugsLasmiditan, Gepants, and Calcitonin-GeneRelated Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1</mixed-citation><mixed-citation xml:lang="en">Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rissardo JP, Caprara ALF. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612</mixed-citation><mixed-citation xml:lang="en">Rissardo JP, Caprara ALF. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Гузий ЕА, Сергеев АВ, Табеева ГР. Оценка эффективности профилактической терапии хронический мигрени с лекарственноиндуцированной головной болью и без нее: данные проспективного исследования. Неврология, нейропсихиатрия, психосоматика. 2024;16(Прил. 1):59-65. doi: 10.14412/2074-2711-2024-1S-59-65.</mixed-citation><mixed-citation xml:lang="en">Guziy EA, Sergeev AV, Tabeeva GR. Evaluation of the efficacy of preventive therapy in chronic migraine with or without medication overuse headache: data from a prospective study. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1S):59-65. doi: 10.14412/2074-2711-2024-1S-59-65 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chhabra N, Mead-Harvey C, Dodoo CA, et al. Blood pressure elevation in erenumabtreated patients with migraine: A retrospective real-world experience. Headache. 2024 Mar;64(3):233-42. doi: 10.1111/head.14679. Epub 2024 Feb 27.</mixed-citation><mixed-citation xml:lang="en">Chhabra N, Mead-Harvey C, Dodoo CA, et al. Blood pressure elevation in erenumabtreated patients with migraine: A retrospective real-world experience. Headache. 2024 Mar;64(3):233-42. doi: 10.1111/head.14679. Epub 2024 Feb 27.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K, Fenton BT, Dao VX, et al. Trajectory of blood pressure after initiating anticalcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. J Headache Pain. 2023 Aug 15;24(1):108. doi: 10.1186/s10194-023-01640-y</mixed-citation><mixed-citation xml:lang="en">Wang K, Fenton BT, Dao VX, et al. Trajectory of blood pressure after initiating anticalcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. J Headache Pain. 2023 Aug 15;24(1):108. doi: 10.1186/s10194-023-01640-y</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134.</mixed-citation><mixed-citation xml:lang="en">Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116.</mixed-citation><mixed-citation xml:lang="en">Sergeev AV, Tabeeva GR, Filatova EG, et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Luo J. Association between migraine and anxiety symptoms: Results from the study of women's health across the nation. J Affect Disord. 2021 Dec 1;295:1229-33. doi: 10.1016/j.jad.2021.09.036. Epub 2021 Sep 17.</mixed-citation><mixed-citation xml:lang="en">Luo J. Association between migraine and anxiety symptoms: Results from the study of women's health across the nation. J Affect Disord. 2021 Dec 1;295:1229-33. doi: 10.1016/j.jad.2021.09.036. Epub 2021 Sep 17.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">McCracken HT, Thaxter LY, Smitherman TA. Psychiatric comorbidities of migraine. Handb Clin Neurol. 2024;199:505-16. doi: 10.1016/B978-0-12-823357-3.00013-6</mixed-citation><mixed-citation xml:lang="en">McCracken HT, Thaxter LY, Smitherman TA. Psychiatric comorbidities of migraine. Handb Clin Neurol. 2024;199:505-16. doi: 10.1016/B978-0-12-823357-3.00013-6</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Lyndon GJ, Prieto R, Wajsbrot DB, et al. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol. 2019 May;34(3):110-8. doi: 10.1097/YIC.0000000000000256</mixed-citation><mixed-citation xml:lang="en">Lyndon GJ, Prieto R, Wajsbrot DB, et al. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol. 2019 May;34(3):110-8. doi: 10.1097/YIC.0000000000000256</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3</mixed-citation><mixed-citation xml:lang="en">Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011 Sep;38(3):567-86. doi: 10.1016/j.ogc.2011.06.002</mixed-citation><mixed-citation xml:lang="en">Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011 Sep;38(3):567-86. doi: 10.1016/j.ogc.2011.06.002</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Schaedel Z, Holloway D, Bruce D, Rymer J. Management of sleep disorders in the menopausal transition. Post Reprod Health. 2021 Dec;27(4):209-14. doi: 10.1177/20533691211039151. Epub 2021 Nov 8.</mixed-citation><mixed-citation xml:lang="en">Schaedel Z, Holloway D, Bruce D, Rymer J. Management of sleep disorders in the menopausal transition. Post Reprod Health. 2021 Dec;27(4):209-14. doi: 10.1177/20533691211039151. Epub 2021 Nov 8.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bakker MH, Hugtenburg JG, Smits MG, et al. Off-label low dose amitriptyline for insomnia disorder: Patient-reported outcomes. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):435-45. doi: 10.1002/pds.5561. Epub 2022 Nov 20.</mixed-citation><mixed-citation xml:lang="en">Bakker MH, Hugtenburg JG, Smits MG, et al. Off-label low dose amitriptyline for insomnia disorder: Patient-reported outcomes. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):435-45. doi: 10.1002/pds.5561. Epub 2022 Nov 20.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023 May;98(5):701-12. doi: 10.1016/j.mayocp.2023.01.010</mixed-citation><mixed-citation xml:lang="en">Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023 May;98(5):701-12. doi: 10.1016/j.mayocp.2023.01.010</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001 Apr 20;38(2):157-63. doi: 10.1016/s0378-5122(00)00215-2</mixed-citation><mixed-citation xml:lang="en">Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001 Apr 20;38(2):157-63. doi: 10.1016/s0378-5122(00)00215-2</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002 Oct;42(9):924-9. doi: 10.1046/j.1526-4610.2002.02215.x. Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310.</mixed-citation><mixed-citation xml:lang="en">Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002 Oct;42(9):924-9. doi: 10.1046/j.1526-4610.2002.02215.x. Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956</mixed-citation><mixed-citation xml:lang="en">Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The HeadHUNT study. Eur J Neurol. 2007 Jan;14(1):73- 8. doi: 10.1111/j.1468-1331.2006.01557.x</mixed-citation><mixed-citation xml:lang="en">Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The HeadHUNT study. Eur J Neurol. 2007 Jan;14(1):73- 8. doi: 10.1111/j.1468-1331.2006.01557.x</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia. 2022 Apr;42(4-5):376-84. doi: 10.1177/03331024211044441. Epub 2021 Sep 27.</mixed-citation><mixed-citation xml:lang="en">Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia. 2022 Apr;42(4-5):376-84. doi: 10.1177/03331024211044441. Epub 2021 Sep 27.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Witten T, Staszkiewicz J, Gold L, et al. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467</mixed-citation><mixed-citation xml:lang="en">Witten T, Staszkiewicz J, Gold L, et al. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Schaudig K, Wang X, Bouchard C, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525.</mixed-citation><mixed-citation xml:lang="en">Schaudig K, Wang X, Bouchard C, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
